227 related articles for article (PubMed ID: 33298585)
21. Rethinking mechanisms of neurotoxicity with BCMA directed therapy.
Mohyuddin GR; Banerjee R; Alam Z; Berger KE; Chakraborty R
Crit Rev Oncol Hematol; 2021 Oct; 166():103453. PubMed ID: 34461271
[TBL] [Abstract][Full Text] [Related]
22. Antibody Drug Conjugates in Multiple Myeloma.
Ferreri CJ; Lee HC
Cancer J; 2022 Nov-Dec 01; 28(6):488-495. PubMed ID: 36383912
[TBL] [Abstract][Full Text] [Related]
23. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
Demel I; Bago JR; Hajek R; Jelinek T
Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
[TBL] [Abstract][Full Text] [Related]
24. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
Sanchez E; Gillespie A; Tang G; Ferros M; Harutyunyan NM; Vardanyan S; Gottlieb J; Li M; Wang CS; Chen H; Berenson JR
Clin Cancer Res; 2016 Jul; 22(13):3383-97. PubMed ID: 26960399
[TBL] [Abstract][Full Text] [Related]
25. Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation.
Bera TK
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33003418
[TBL] [Abstract][Full Text] [Related]
26. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma.
Elkins K; Zheng B; Go M; Slaga D; Du C; Scales SJ; Yu SF; McBride J; de Tute R; Rawstron A; Jack AS; Ebens A; Polson AG
Mol Cancer Ther; 2012 Oct; 11(10):2222-32. PubMed ID: 22807577
[TBL] [Abstract][Full Text] [Related]
27. Tumor therapy with Amanita phalloides (death cap): stabilization of B-cell chronic lymphatic leukemia.
Riede I
J Altern Complement Med; 2010 Oct; 16(10):1129-32. PubMed ID: 20954964
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma.
Fang Y; Hou J
Mil Med Res; 2021 Jan; 8(1):9. PubMed ID: 33504363
[TBL] [Abstract][Full Text] [Related]
29. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
[TBL] [Abstract][Full Text] [Related]
30. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
[TBL] [Abstract][Full Text] [Related]
31. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
[TBL] [Abstract][Full Text] [Related]
32. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.
Sherbenou DW; Aftab BT; Su Y; Behrens CR; Wiita A; Logan AC; Acosta-Alvear D; Hann BC; Walter P; Shuman MA; Wu X; Atkinson JP; Wolf JL; Martin TG; Liu B
J Clin Invest; 2016 Dec; 126(12):4640-4653. PubMed ID: 27841764
[TBL] [Abstract][Full Text] [Related]
33. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
34. Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide.
Works M; Soni N; Hauskins C; Sierra C; Baturevych A; Jones JC; Curtis W; Carlson P; Johnstone TG; Kugler D; Hause RJ; Jiang Y; Wimberly L; Clouser CR; Jessup HK; Sather B; Salmon RA; Ports MO
Mol Cancer Ther; 2019 Dec; 18(12):2246-2257. PubMed ID: 31395689
[TBL] [Abstract][Full Text] [Related]
35. BCMA-targeted immunotherapy for multiple myeloma.
Yu B; Jiang T; Liu D
J Hematol Oncol; 2020 Sep; 13(1):125. PubMed ID: 32943087
[TBL] [Abstract][Full Text] [Related]
36. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
[TBL] [Abstract][Full Text] [Related]
37. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma.
Wang Y; Li H; Xu W; Pan M; Qiao C; Cai J; Xu J; Wang M; Zhang J
J Immunother; 2020; 43(6):175-188. PubMed ID: 32349046
[TBL] [Abstract][Full Text] [Related]
38. Antibody treatment in multiple myeloma.
Maples KT; Johnson C; Lonial S
Clin Adv Hematol Oncol; 2021 Mar; 19(3):166-174. PubMed ID: 33739965
[TBL] [Abstract][Full Text] [Related]
39. B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma.
Eckhert E; Hewitt R; Liedtke M
Immunotherapy; 2019 Jun; 11(9):801-811. PubMed ID: 31094254
[TBL] [Abstract][Full Text] [Related]
40. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys.
Goldstein RL; Goyos A; Li CM; Deegen P; Bogner P; Sternjak A; Thomas O; Klinger M; Wahl J; Friedrich M; Rattel B; Lamas E; Min X; Sudom A; Farshbaf M; Coxon A; Balazs M; Arvedson T
Blood Adv; 2020 Sep; 4(17):4180-4194. PubMed ID: 32886754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]